Venous thromboembolism in cervical cancer

The Lancet Oncology

Volumn 9, Issue 1, 2008, Pages 54-60

  Barbera, Lisa ^a,b   Thomas, Gillian ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CISPLATIN; FLUOROURACIL; HEMOGLOBIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; OXYPHENBUTAZONE; THROMBOPLASTIN;

ADJUVANT THERAPY; ANTICOAGULATION; ARTERY THROMBOSIS; BRACHYTHERAPY; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CYTOKINE RELEASE; HEART INFARCTION; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; HYSTERECTOMY; INCIDENCE; LUNG EMBOLISM; LYMPH NODE DISSECTION; MONOTHERAPY; MORTALITY; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROGNOSIS; RAYNAUD PHENOMENON; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; UTERINE CERVIX CANCER; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

COMBINED MODALITY THERAPY; FEMALE; HUMANS; INCIDENCE; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; UTERINE CERVICAL NEOPLASMS; VENOUS THROMBOEMBOLISM;

EID: 37449012538     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(07)70409-6     Document Type: Review

References (76)

1. Sorensen H., Mellemkjaer L., Olsen J., and Baron J. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343 (2000) 1846-1850
2. Morgan M., Iyengar T., Napiorkowski B., Rubin S., and Mikuta J. The clinical course of deep vein thrombosis in patients with gynecologic cancer. Gynecol Oncol 84 (2002) 67-71
3. Thomas G., Ali S., Patel M., Abulafia O., and Lucci J. A GOG phase III trial to evaluate maintaining hemoglobin >=120 g/l with erythropoietin during chemoradiation for cervical cancer. Int J Gynecol Cancer 16 suppl 3 (2006) 603
4. Kabbinavar F., Hurwitz H., Fehrenbacher L., et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21 (2003) 60-65
5. Wang X., Fu S., Freedman R., and Kavanagh J. Venous thromboembolism syndrome in gynecological cancer. Int J Gynecol Cancer 16 suppl 1 (2006) 458-471
6. Heit J. Cancer and venous thromboembolism: scope of the problem. Cancer Control 12 Suppl 1 (2005) 5-10
7. Lee A. Cancer and thromboembolic disease: pathogenic mechanisms. Cancer Treat Rev 28 (2002) 137-140
8. Lee A., and Levine M. Venous thromboembolism and cancer: risks and outcomes. Circulation 107 23 suppl 1 (2003) I17-I21
9. Anders J., Grigsby P., and Singh A. Cisplatin chemotherapy (without erythropoietin) and risk of life-threatening thromboembolic events in carcinoma of the uterine cervix: the tip of the iceberg? A review of the literature. Radiat Oncol 1 (2006) 14
10. National Cancer Institute. CTC v2.0 and common terminology criteria for adverse events v3.0 (CTCAE). NCI cancer therapy evaluation program (2007). http://ctep.cancer.gov/reporting/ctc.html (accessed Oct 13, 2007).
11. Dickson B. Venous thrombosis: on the history of Virchow's Traid. Univ Toronto Med J 81 (2004) 166-171
12. Silverstein M., Heit J., Mohr D., Petterson T., O'Fallon W., and Melton III L. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 158 (1998) 585-593
13. Heit J., Silverstein M., Mohr D., Petterson T., O'Fallon W., and Melton III L. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160 (2000) 809-815
14. Samama M., Dahl O., Quinlan D., Mismetti P., and Rosencher N. Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool. Haematologica 88 (2003) 1410-1421
15. Alikhan R., Cohen A., Combe S., et al. Risk Factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX study. Arch Intern Med 164 (2004) 963-968
16. Samama M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 160 (2000) 3415-3420
17. Haddad T., and Greeno E. Chemotherapy-induced thrombosis. Thromb Res 118 (2006) 555-568
18. Rickles F., and Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res 102 (2001) V215-V224
19. Staging classifications and clinical practice guidelines for gynaecological cancers. http://www.figo.org/docs/staging_booklet.pdf (accessed Nov 13, 2007).
20. Gadducci A., Baicchi U., Marrai R., et al. Pretreatment plasma levels of fibrinopeptide-A (FPA), D-dimer (DD), and von Willebrand factor (vWF) in patients with operable cervical cancer: influence of surgical-pathological stage, tumor size, histologic type, and lymph node status. Gynecol Oncol 49 (1993) 354-358
21. Sallah S., Wan J., and Nguyen N. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 87 (2002) 575-579
22. De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol 50 (2004) 187-196
23. Gouin-Thibault I., Achkar A., and Samama M. The thrombophilic state in cancer patients. Acta Haematol 106 (2001) 33-42
24. Prandoni P., Falanga A., and Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 6 (2005) 401-410
25. Keys H., Bundy B., Stehman F., et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. New Engl J Med 340 (1999) 1154-1161
26. Morris M., Eifel P., Lu J., et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. New Engl J Med 340 (1999) 1137-1143
27. Rose P., Bundy B., Watkins E., et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. New Engl J Med 340 (1999) 1144-1153
28. Whitney C., Sause W., Bundy B., et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 17 (1999) 1339-1348
29. Peters III W., Liu P., Barrett R., et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 18 (2000) 1606-1613
30. Sedlis A., Bundy B., Rotman M., Lentz S., Muderspach L., and Zaino R. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group Study. Gynecol Oncol 73 (1999) 177-183
31. Clarke-Pearson D., Jelovsek F., and Creasman W. Thromboembolism complicating surgery for cervical and uterine malignancy: incidence, risk factors, and prophylaxis. Obstet Gynecol 61 (1983) 87-94
32. Martino M., Borges E., Williamson E., et al. Pulmonary embolism after major abdominal surgery in gynecologic oncology. Obstet Gynecol 107 (2006) 666-671
33. Panici P.B., Plotti F., Zullo M., et al. Pelvic lymphadenectomy for cervical carcinoma: laparotomy extraperitoneal, transperitoneal or laparoscopic approach? A randomized study. Gynecol Oncol 103 (2006) 859-864
34. Jackson K., Das N., Naik R., et al. Laparoscopically assisted radical vaginal hysterectomy vs. radical abdominal hysterectomy for cervical cancer: a match controlled study. Gynecol Oncol 95 (2004) 655-661
35. Panici P.B., Maneschi F., Cutillo G., et al. Modified type IV-V radical hysterectomy with systematic pelvic and aortic lymphadenectomy in the treatment of patients with stage III cervical carcinoma. Feasibility, technique, and clinical results. Cancer 78 (1996) 2359-2365
36. Greer B., Figge D., Tamimi H., and Cain J. Stage IB adenocarcinoma of the cervix treated by radical hysterectomy and pelvic lymph node dissection. Am J Obstet Gynecol 160 (1989) 1509-1513
37. Leath III C., Straughn Jr. J., Estes J., et al. The impact of aborted radical hysterectomy in patients with cervical carcinoma. Gynecol Oncol 95 (2004) 204-207
38. Sivanesaratnam V., Sen D., Jayalakshmi P., and Ong G. Radical hysterectomy and pelvic lymphadenectomy for early invasive cancer of the cervix-14-year experience. Int J Gynecol Cancer 3 (1993) 231-238
39. Steed H., Rosen B., Murphy J., Laframboise S., De Petrillo D., and Covens A. A comparison of laparascopic-assisted radical vaginal hysterectomy and radical abdominal hysterectomy in the treatment of cervical cancer. Gynecol Oncol 93 (2004) 588-593
40. Landoni F., Maneo A., Colombo A., et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 350 (1997) 535-540
41. Vale C., and Tierney J. Concomittant chemoradiation for cervical cancer: a meta-analysis using individual patient data from randomized controlled trials. Int J Gynecol Cancer 16 suppl 3 (2006) 603
42. Pearcey R., Brundage M., Drouin P., et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol 20 (2002) 966-972
43. Togna G., Togna A., Franconi M., and Caprino L. Cisplatin triggers platelet activation. Thromb Res 99 (2000) 503-509
44. Icli F., Karaoguz H., Dincol D., et al. Severe vascular toxicity associated with cisplatin-based chemotherapy. Cancer 72 (1993) 587-593
45. Hennessy B., O'Connor M., and Carney D. Acute vascular events associated with cisplatin therapy in malignant disease. Ir Med J 95 (2002) 145-146 148.
46. Corn B., Shaktman B., Lanciano R., et al. Intra- and perioperative complications associated with tandem and colpostat application for cervix cancer. Gynecol Oncol 64 (1997) 224-229
47. Jacobson G., Kamath R., Smith B., and Goodheart M. Thromboembolic events in patients treated with definitive chemotherapy and radiation therapy for invasive cervical cancer. Gynecol Oncol 96 (2005) 470-474
48. Jhingran A., and Eifel P. Perioperative and postoperative complications of intracavitary radiation for FIGO stage I-III carcinoma of the cervix. Int J Radiat Oncol Biol Phys 46 (2000) 1177-1183
49. Lambin P., Gerbaulet A., Kramar A., et al. Phase III trial comparing two low dose rates in brachytherapy of cervix carcinoma: report at two years. Int J Radiat Oncol Biol Phys 25 (1993) 405-412
50. Lanciano R., Corn B., Martin E., Schultheiss T., Hogan W., and Rosenblum N. Perioperative morbidity of intracavitary gynecologic brachytherapy. Int J Radiat Oncol Biol Phys 29 (1994) 969-974
51. Temkin S., Hellmann M., Serur E., Lee Y., and Abulafia O. Erythropoietin administration during primary treatment for locally advanced cervical carcinoma is associated with poor response to radiation. Int J Gynecol Cancer 16 (2006) 1855-1861
52. Wun T., Law L., Harvey D., Sieracki B., Scudder S., and Ryu J. Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer 98 (2003) 1514-1520
53. Potter R., Dimopoulos J., Bachtiary B., et al. 3D conformal HDR-brachy- and external beam therapy plus simultaneous cisplatin for high-risk cervical cancer: Clinical experience with 3 year follow-up. Radiother Oncol 79 (2006) 80-86
54. Hallahan D., Chen A., Teng M., and Cmelak A. Drug-radiation interactions in tumor blood vessels. Oncology (Williston Park) 13 10 Suppl 5 (1999) 71-77
55. van Kleef E., Verheij M., te Poele H., Oussoren Y., Dewit L., and Stewart F. In vitro and in vivo expression of endothelial von Willebrand factor and leukocyte accumulation after fractionated irradiation. Radiat Res 154 (2000) 375-381
56. Uszynski M., Miodonska J., and Zekanowska E. Transient increase in thrombin generation during radiotherapy of uterine carcinoma: a preliminary study using thrombin-antithrombin III complex measurements. Gynecol Obstet Invest 46 (1998) 130-132
57. Grogan M., Thomas G., Melamed I., et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 86 (1999) 1528-1536
58. Bohlius J., Wilson J., Seidenfeld J., et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98 (2006) 708-714
59. Dusenbery K., McGuire W., Holt P., et al. Erythropoietin increases hemoglobin during radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys 29 (1994) 1079-1084
60. Lin A., Ryu J., Harvey D., Sieracki B., Scudder S., and Wun T. Low-dose warfarin does not decrease the rate of thrombosis in patients with cervix and vulvo-vaginal cancer treated with chemotherapy, radiation, and erythropoietin. Gynecol Oncol 102 (2006) 98-102
61. Lavey R., Liu P., Greer B., et al. Recombinant human erythropoietin as an adjunct to radiation therapy and cisplatin for stage IIB-IVA carcinoma of the cervix: a Southwest Oncology Group study. Gynecol Oncol 95 (2004) 145-151
62. Henke M., Laszig R., Rube C., et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362 (2003) 1255-1260
63. Leyland-Jones B., Semiglazov V., Pawlicki M., et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23 (2005) 5960-5972
64. Henke M., Mattern D., Pepe M., et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings?. J Clin Oncol 24 (2006) 4708-4713
65. Wright J., Viviano D., Powell M., et al. Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. Gynecol Oncol 103 (2006) 489-493
66. Lip G., Chin B., and Blann A. Cancer and the prothrombotic state. Lancet Oncol 3 (2002) 27-34
67. Rickles F., Patierno S., and Fernandez P. Tissue factor, thrombin, and cancer. Chest 124 3 Suppl (2003) 58S-68S
68. Einstein M., Pritts E., and Hartenbach E. Venous thromboembolism prevention in gynecologic cancer surgery: a systematic review. Gynecol Oncol 105 (2007) 813-819
69. Geerts W., Pineo G., Heit J., et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (2004) 338S-400S
70. Buller H., Agnelli G., Hull R., Hyers T., Prins M., and Raskob G. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (2004) 401S-428S
71. Hejna M., Raderer M., and Zielinski C. Inhibition of metastases by anticoagulants. J Natl Cancer Inst 91 (1999) 22-36
72. von Tempelhoff G., Harenberg J., Niemann F., Hommel G., Kirkpatrick C., and Heilmann L. Effect of low molecular weight heparin (certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial. Int J Oncol 16 (2000) 815-824
73. Weppelmann B., and Monkemeier D. The influence of prostaglandin antagonists on radiation therapy of carcinoma of the cervix. Gynecol Oncol 17 (1984) 196-199
74. Lee A., Rickles F., Julian J., et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 23 (2005) 2123-2129
75. Kakkar A., Levine M., Kadziola Z., et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 22 (2004) 1944-1948
76. Klerk C., Smorenburg S., Otten H., et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23 (2005) 2130-2135